Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

NCT01011166 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG: IDX184
DRUG: Placebo
BIOLOGICAL: Peginterferon alfa-2a (Peg-IFN)
DRUG: Ribavirin (RBV)

Sponsor

Merck Sharp & Dohme LLC